相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis
Raphael Szalat et al.
LEUKEMIA (2021)
A pharmacist's review of the treatment of systemic light chain amyloidosis
David M. Hughes et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis
Giovanni Palladini et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2021)
Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
Giovanni Palladini et al.
CELLS (2021)
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data
Sriram Ravichandran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
Philippe Moreau et al.
LANCET (2021)
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
I. Vaxman et al.
LEUKEMIA (2021)
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
E. Kastritis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population
Zoe Van de Wyngaert et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature
Ramon Lecumberri et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2020)
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study
Vaishali Sanchorawala et al.
BLOOD (2020)
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria
Christoph R. Kimmich et al.
BLOOD (2020)
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
Meera Mohan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
Giovanni Palladini et al.
BLOOD (2020)
Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen
Brett Dumas et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2020)
Management of AL amyloidosis in 2020
Giovanni Palladini et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms
Lisa Xingguang Lee et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2019)
Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis
Brian Lilleness et al.
BLOOD (2019)
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
Sandy W. Wong et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Systemic immunoglobulin light chain amyloidosis
Giampaolo Merlini et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis
Martin Granzow et al.
HAEMATOLOGICA (2017)
Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis
Martin Granzow et al.
HAEMATOLOGICA (2017)
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
Gregory P. Kaufman et al.
BLOOD (2017)
AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis
Tobias Dittrich et al.
BLOOD (2017)
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study
Tilmann Bochtler et al.
BLOOD (2016)
Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens
Tilmann Bochtler et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone
Tilmann Bochtler et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2014)
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2014)
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2013)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
R. L. Comenzo et al.
LEUKEMIA (2012)
Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)
Tilmann Bochtler et al.
BLOOD (2011)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
